Effect of brimonidine 0.5% on intraocular pressure spikes following 360° argon laser trabeculoplasty

A. L. Robin; R. David; L. Shani; H. Barnebey; C. E. Clevenger; T. J. Zimmerman; G. Nardin; S. B. Hersh; J. C. Morrison; G. L. Spaeth; L. J. Katz; H. F. Perell; L. I. Siegel; R. A. Lewis; J. C. Henry; A. L. Coleman; D. A. Lee; M. C. Stiles; M. S. Passo

Effect of brimonidine 0.5% on intraocular pressure spikes following 360° argon laser trabeculoplasty

A. L. Robin, R. David, L. Shani, H. Barnebey, C. E. Clevenger, T. J. Zimmerman, G. Nardin, S. B. Hersh, J. C. Morrison, G. L. Spaeth, L. J. Katz, H. F. Perell, L. I. Siegel, R. A. Lewis, J. C. Henry, A. L. Coleman, D. A. Lee, M. C. Stiles, M. S. Passo

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Background and Objective: Brimonidine tartrate 0.5%, a topical alpha₂-adrenergic agonist, was administered before and after argon laser trabeculoplasty (ALT) to evaluate its efficacy against postoperative intraocular pressure (IOP) spikes. Patients and Methods: Two randomized, double-masked, vehicle-controlled investigations evaluated four treatment regimens in 471 patients undergoing ALT for glaucoma or ocular hypertension. The combined results are presented. Results: IOP elevations ≥ 10 mmHg occured in 1% (1/122) of the patients who received brimonidine before and after ALT; in 2% (2/119) of those receiving brimonidine before and vehicle after; in 1% (1/114) of those receiving vehicle before and brimonidine after; and in 23% (27/116) of those receiving vehicle before and after (P < .001). Conclusion: The brimonidine regimens were generally effective and well-tolerated ocularly and systemically.

Original language	English (US)
Pages (from-to)	404-409
Number of pages	6
Journal	Ophthalmic Surgery and Lasers
Volume	26
Issue number	5
State	Published - 1995
Externally published	Yes

ASJC Scopus subject areas

Ophthalmology

Cite this

Robin, A. L., David, R., Shani, L., Barnebey, H., Clevenger, C. E., Zimmerman, T. J., Nardin, G., Hersh, S. B., Morrison, J. C., Spaeth, G. L., Katz, L. J., Perell, H. F., Siegel, L. I., Lewis, R. A., Henry, J. C., Coleman, A. L., Lee, D. A., Stiles, M. C., & Passo, M. S. (1995). Effect of brimonidine 0.5% on intraocular pressure spikes following 360° argon laser trabeculoplasty. Ophthalmic Surgery and Lasers, 26(5), 404-409.

Robin, AL, David, R, Shani, L, Barnebey, H, Clevenger, CE, Zimmerman, TJ, Nardin, G, Hersh, SB, Morrison, JC, Spaeth, GL, Katz, LJ, Perell, HF, Siegel, LI, Lewis, RA, Henry, JC, Coleman, AL, Lee, DA, Stiles, MC & Passo, MS 1995, 'Effect of brimonidine 0.5% on intraocular pressure spikes following 360° argon laser trabeculoplasty', Ophthalmic Surgery and Lasers, vol. 26, no. 5, pp. 404-409.

@article{5a1c178158be4cd5ab8e7d99af407d22,

title = "Effect of brimonidine 0.5% on intraocular pressure spikes following 360° argon laser trabeculoplasty",

abstract = "Background and Objective: Brimonidine tartrate 0.5%, a topical alpha2-adrenergic agonist, was administered before and after argon laser trabeculoplasty (ALT) to evaluate its efficacy against postoperative intraocular pressure (IOP) spikes. Patients and Methods: Two randomized, double-masked, vehicle-controlled investigations evaluated four treatment regimens in 471 patients undergoing ALT for glaucoma or ocular hypertension. The combined results are presented. Results: IOP elevations ≥ 10 mmHg occured in 1% (1/122) of the patients who received brimonidine before and after ALT; in 2% (2/119) of those receiving brimonidine before and vehicle after; in 1% (1/114) of those receiving vehicle before and brimonidine after; and in 23% (27/116) of those receiving vehicle before and after (P < .001). Conclusion: The brimonidine regimens were generally effective and well-tolerated ocularly and systemically.",

author = "Robin, {A. L.} and R. David and L. Shani and H. Barnebey and Clevenger, {C. E.} and Zimmerman, {T. J.} and G. Nardin and Hersh, {S. B.} and Morrison, {J. C.} and Spaeth, {G. L.} and Katz, {L. J.} and Perell, {H. F.} and Siegel, {L. I.} and Lewis, {R. A.} and Henry, {J. C.} and Coleman, {A. L.} and Lee, {D. A.} and Stiles, {M. C.} and Passo, {M. S.}",

year = "1995",

language = "English (US)",

volume = "26",

pages = "404--409",

journal = "Ophthalmic Surgery and Lasers",

issn = "1082-3069",

publisher = "Slack Incorporated",

number = "5",

}

TY - JOUR

T1 - Effect of brimonidine 0.5% on intraocular pressure spikes following 360° argon laser trabeculoplasty

AU - Robin, A. L.

AU - David, R.

AU - Shani, L.

AU - Barnebey, H.

AU - Clevenger, C. E.

AU - Zimmerman, T. J.

AU - Nardin, G.

AU - Hersh, S. B.

AU - Morrison, J. C.

AU - Spaeth, G. L.

AU - Katz, L. J.

AU - Perell, H. F.

AU - Siegel, L. I.

AU - Lewis, R. A.

AU - Henry, J. C.

AU - Coleman, A. L.

AU - Lee, D. A.

AU - Stiles, M. C.

AU - Passo, M. S.

PY - 1995

Y1 - 1995

N2 - Background and Objective: Brimonidine tartrate 0.5%, a topical alpha2-adrenergic agonist, was administered before and after argon laser trabeculoplasty (ALT) to evaluate its efficacy against postoperative intraocular pressure (IOP) spikes. Patients and Methods: Two randomized, double-masked, vehicle-controlled investigations evaluated four treatment regimens in 471 patients undergoing ALT for glaucoma or ocular hypertension. The combined results are presented. Results: IOP elevations ≥ 10 mmHg occured in 1% (1/122) of the patients who received brimonidine before and after ALT; in 2% (2/119) of those receiving brimonidine before and vehicle after; in 1% (1/114) of those receiving vehicle before and brimonidine after; and in 23% (27/116) of those receiving vehicle before and after (P < .001). Conclusion: The brimonidine regimens were generally effective and well-tolerated ocularly and systemically.

AB - Background and Objective: Brimonidine tartrate 0.5%, a topical alpha2-adrenergic agonist, was administered before and after argon laser trabeculoplasty (ALT) to evaluate its efficacy against postoperative intraocular pressure (IOP) spikes. Patients and Methods: Two randomized, double-masked, vehicle-controlled investigations evaluated four treatment regimens in 471 patients undergoing ALT for glaucoma or ocular hypertension. The combined results are presented. Results: IOP elevations ≥ 10 mmHg occured in 1% (1/122) of the patients who received brimonidine before and after ALT; in 2% (2/119) of those receiving brimonidine before and vehicle after; in 1% (1/114) of those receiving vehicle before and brimonidine after; and in 23% (27/116) of those receiving vehicle before and after (P < .001). Conclusion: The brimonidine regimens were generally effective and well-tolerated ocularly and systemically.

UR - http://www.scopus.com/inward/record.url?scp=0028805185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028805185&partnerID=8YFLogxK

M3 - Article

C2 - 8963853

AN - SCOPUS:0028805185

SN - 1082-3069

VL - 26

SP - 404

EP - 409

JO - Ophthalmic Surgery and Lasers

JF - Ophthalmic Surgery and Lasers

IS - 5

ER -

Effect of brimonidine 0.5% on intraocular pressure spikes following 360° argon laser trabeculoplasty

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this